<DOC>
	<DOCNO>NCT00835094</DOCNO>
	<brief_summary>This open-label , randomize , parallel-group comparison mometasone furoate dry powder inhaler ( MF-DPI ) 400 mcg daily administer morning vs. even 12 week subject asthma .</brief_summary>
	<brief_title>A Randomized Trial Assessing Once Daily Administration Mometasone Furoate DPI Asthmatics ( Study P02177 )</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Mometasone Furoate</mesh_term>
	<criteria>Subjects ( parent/guardian subject &lt; 18 ) must demonstrate willingness participate study comply procedure sign write informed consent . Subjects must &gt; =12 year age ( unless restrict old age local ethical committee national health authority ) , either gender race . Subjects must history asthma &gt; =6 month . If subject take inhaled corticosteroid , daily dose must &lt; = upper limit define : budesonide &lt; =800 mcg/day triamcinolone acetonide &lt; =800 mcg/day beclomethasone dipropionate &lt; =1000 mcg/day fluticasone propionate &lt; =500 mcg/day flunisolide &lt; =1000 mcg/day Women childbearing potential must negative urine ( hCG ) pregnancy test day randomization ( Baseline visit ) . Women childbearing potential ( include woman &lt; 1 year postmenopausal ) must use acceptable method birth control ( eg , hormonal contraceptive , medically prescribe IUD , condom combination spermicide ) surgically sterilize ( eg , hysterectomy tubal ligation ) . Subjects must agree inform usual treating physician ( study investigator ) participation study . Female subject pregnant , breastfeeding , premenarcheal . Subjects require daily alternate day oral corticosteroid treatment total 14 day 6 month immediately prior Visit 1 , and/or subject require course systemic corticosteroid within previous month . Subjects either asthma exacerbation clinically relevant change asthma medication within last 4 week . Subjects admit hospital asthma control within previous 3 month within previous 6 month . Subjects require ventilator support respiratory failure secondary asthma within last 5 year . Subjects use investigational drug 30 day prior Baseline , subject treated investigational antibody asthma 90 day prior Baseline . Subjects allergic idiosyncratic reaction corticosteroid . Subjects clinically significant disorder cardiovascular , neurologic , hematologic , gastrointestinal , cerebrovascular , immunologic system , respiratory disease asthma ( eg , COPD ) , disorder may interfere study evaluation affect subject safety . Subjects history drug abuse , poor motivation , hypochondriasis , emotional intellectual problem likely limit validity consent participate study .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>